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Summary Anti-p53 antibodies in sera are known to be products of the host immune response to mutated p53 protein, and are present in
some patients with various types of cancer. In this study, we measured serum anti-p53 antibody levels in 52 patients with lung cancer and 63
normal volunteers to determine the relationship between anti-p53 antibody level and clinical features of lung cancer patients. Anti-p53
antibody level was measured by an enzyme-linked immunosorbent assay and expressed as an anti-p53 antibody index, defined as the ratio
of absorption of serum sample to that of p53-positive serum. The median anti-p53 antibody index was 6.6 for lung cancer patients, and higher
than that in normal volunteers (1.7) (P= 0.0000). For lung cancer patients, significant differences in index levels were found by histology (4.3,
n = 25, adenocarcinoma vs 8.7. n = 18, squamous cell carcinoma vs 64.8, n = 2, large-cell carcinoma vs 9.8, n = 7, small-cell carcinoma;
P= 0.0109). High anti-p53 antibody index levels were observed for both large-cell carcinoma and small-cell carcinoma. When the cut-off level
was set at 7.2, determined using the twice 95% specificity level for normal volunteers, the sensitivities of anti-p53 antibodies were 46.1% for
all lung cancers, 28.0% for adenocarcinoma, 55.6% for squamous cell carcinoma, 100% for large-cell carcinoma and 71.4% for small-cell
carcinoma. However, there were no significant differences in index level by gender, age, smoking index, presence of previous or concomitant
cancer or disease stage. Mulfivariate analysis using a logistic regression model demonstrated that histological type of tumour was a dominant
factor associated with elevation of anti-p53 antibody index level (P= 0.0184). These findings suggest that serum anti-p53 antibody index level
might be independent of tumour burden and the presence of previous or concomitant cancer in our series of lung cancer patients, but is
clearly strongly correlated with tumour histological type.
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The p53 tumour-suppressor gene encompasses 16-20 kb of
cellular DNA located on the short arm of human chromosome 17
(Levine et al. 1991f. This gene is involved in control of the cell
cycle. DNA synthesis and repair. cell differentiation. genomic
plasticity and programmed cell death (Harris et al. 1993).
Mutations of the p53 gene are currently the most common genetic
alteration identified in human cancers (Levine et al. 1991: Harris
and Hollstein 1993: Chang et al. 1995).
The p53 gene product. p53 protein. is generally present at low
levels in normal tissues and cannot usually be detected using
conventional immunoprecipitation or immunohistochemical
methods. How-ever. in more than half of common cancers.
dramatic accumulation of p53 protein is readily detected both
histochemicallv and by quantitative enzyme-linked immunosor-
bent assav (ELISA) and immunoblotting technique (Hollstein et
al. 1991: Lesine et al. 1991). Missense mutations that lead to a
prolonged half-life of p53 protein are principally responsible for
the detection ofthis protein (Levine et al. 1991)
Mutant p53 proteins are known to be targets of host immune
svstems (Craw-fort et al. 1982). Examination of serum has shown
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that some patients with cancers that harbour a mutated p53 allele
have mounted a humoral immune response to abnormal levels of
p53 protein. Anti-p53 antibodies (anti-p53) have been demon-
strated in up to 26% ofpatients v% ith various malignant conditions.
including breast. lung. colorectal and liver tumours. as well as
lymphomas (Craw-fort et al. 1982: Caron de Fromentel et al. 1987.
Davidoff et al. 1992: Schhchtholz et al. 1992. 1994: Winter et al.
1992. 1993: Labrecque et al. 1993: Lubin et al. 1993: Green et al.
1994: Mudenda et al. 1994: Muller et al. 1994: Chang et al. 1995).
For breast cancer patients. the presence of anti-p53 in serum is
significantly correlated with high-grade histologv. historv of
second primary cancer and poor prognosis (Mudenda et al. 1994:
Peyrat et al. 1995). In addition. the potential for early diagnosis of
cancer bv detection of anti-p53 has been noted. as emergence of
serum anti-p53 was demonstrated before clinical detection of
cancers among a subset of a non-cancer cohort (Lubin et al. 1995:
Trivers et al. 1995. 1996).
We assessed serum p53 protein levels in a series of small-cell
lung cancer patients in a previous study: however. only a fez of
the patients Sue studied exhibited an elevated p53 protein level
(Segaawa et al. 1997ai. Therefore. in the present study. xe
measured serum anti-p53 levels in patients newtly diagnosed with
lung cancer using an ELISA method and examined the relation-
ship between anti-p53 level and clinical features of lung cancer
patients in order to determine the clinical significance of serum
anti-p53 values for lung cancer patients.
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Table 1 Patient characteristics
Lung cancer Normal -ouMe P-value
No. of subjects 52 63
Male/temaie 32/20 29/34 0.0972
Median years of age (range) 68 (46-85) 29 (20-69) 0.0000
Presence of previous or concomitant cancer
No/yes 4517a 63/0 0.0027
Smoking index
< 6001 600 20/32
Histology
Adenocarcinoma 25
Squamous cell carcinoma 18
Large-cell carcinoma 2
Small-cell carcnom 7
Stage
17
IIIA 4
IIIB 14
IV 17
aFrve patients had a history ofdiagnosis of a separate cancer morethan 1 year beore thediagnosis of lung cancer, and two
patients had an addiional concomitant cancer.
MATERIALS AND METHODS
Patints
This prospective study employed serum samples obtained from 52
patients with lung cancer and 63 normal volunteers (Table 1).
Recruitment of lung cancer patients and normal volunteers was
performed between October 1996 and May 1997 after written
informed consent had been obtained in accordance with our insti-
tutional guidelines. The patients with lung cancer had all been
newly diagnosed with lung cancer at our hospital during this
period. The patients with lung cancer included 32 men and 20
women (median age. 68 years), whereas the normal volunteers
included 29 men and 34 women (median age, 29 years). There
were 32 heavy smokers (smoking index 600) in the lung cancer
group. Five of the lung cancer patients had a history ofdiagnosis
of a separate cancer more than 1 year before the diagnosis oflung
cancer (uterine cancer in two patients, and tongue, bladder and
rectal cancer in one patient each), and two patients (one each) had
a concomitant laryngeal cancer and carcinomatous cervical
lymphadenopathy with a different histological type from that of
lung cancer. None ofthe normal volunteers had ahistory ofcancer.
All the patients with lung cancerunderwent a series ofexamina-
tions for staging as previously described (Segawa et al, 1997b),
and were classified using the tumour-node-metastasis system
(Mountain et al, 1986): stage I disease was found in 17 patients,
[IA in 4, iHIB in 14 and IV in 17. Histological classification of
tumours was based on the World Health Organization criteria (The
World Health Organization, 1982). There were 25 adenocarci-
nomas, 18 squamous cell carcinomas, two large-cell carcinomas
and seven small-cell carcinomas.
Measurement of serum anti-p53 index levels
Serum samples were obtained from subjects (at the time of diag-
nosis in the case oflung cancerpatients) and stored at - 70'C until
measurement. Anti-p53 index levels were determined using an
ELISA kit (Dianova, Germany). Briefly. serum samples were
diluted 1:100 in the sample dilution buffer prepared with the kit
before assay. The samples were added to 96-microtitre wells
precoated with human recombinant p53 protein and incubated at
370C for 1 h. After washing, anti-p53 antibodies that attached to
the protein of each well were bound by peroxidase-conjugated
goat anti-human IgG. Colour wasdeveloped with the chromogenic
substrate tetramethylbenzidine, and the absorbance of each well
was determined using a microplate reader at a wavelength of450
nm (Bio-rad, USA). The anti-p53 index was calculated using the
formula: [A450 (serum sample) -A450 (anti-p53-negative
serum)J/[A450 (anti-p53-positive serum) -A450 (anti-p53-nega-
tive serum)] x 100. Following the directions given in the manual
for this kit, the anti-p53-positive serum was tested forthe presence
of anti-p53 by immunoblotting assay. All the samples were
measured in duplicate. Mean values of anti-p53 indexes for each
sample were used foranalyses in this study. In addition, the coeffi-
cients ofvariation tested for three samples from normal volunteers
ranged from 3.2% to 8.7%.
Immunoblotting analysis of serum antI-3
Fourteen serum samples obtained from lung cancer patients were
tested for the presence ofanti-p53 by an immunoblotting method.
These samples exhibited a consecutively increasing anti-p53 index
level in our series (Figure 1). Our immunoblotting procedure was
described previously (Segawa et al, 1997a). Briefly, an aliquot of
1 x 106 p53 protein-positive HEL 92.1.7 cells (American Type
Culture Collection, USA) was lysed in phosphate-buffered saline
(PBS) containing 0.25 M sucrose, 0.01% ethylenedianiinete-
traacetic acid disodium salt, 2 mm phenylmethylsulfonyl fluoride,
0.02% sodium nitride, and 0.5% Nonidet P-40 and ultrasonicated
for40 s. Aftercentrifugation at 10 000 xg for 60 min. I)0gI ofthe
lysate was combined with the same volume ofsample buffer (0.25
M Tris. 20% glycerol. 4% sodium dodecyl sulphate. 0.05%
bromophenol blue, 10% S-mercaptoethanol) and boiled for 5 min.
Then. 10g1 of the sample was loaded into individual wells of a
10% polyacrylamide gel, electrophoretically separated and trans-
ferred to nitrocellulose membrane. After blocking with PBS
containing 1% skim milk, separated pieces ofthe membrance were
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incubated with individual patient serum (a 1:250 dilution in PBS
containing 1% skim milk) at room temperature for 1 h. Mouse
monoclonal anti-p53 antibody OD-7 (1:500 dilution: Dako.
Denmark) and PBS containing 1% skim milk were used as positive
and negative controls respectively. After washing with PBS
containing 0.1% Tween 20. the membranes were incubated with a
1:500 dilution of alkaline phosphatase-conjugated goat anti-
human IgG (Jackson Immunoresearch. USA) or of peroxidase-
conjugated goat anti-mouse IgG (Tago. USA). Colour was
developed with the chromogenic substrates nitrotetrazolium blue
or diaminobenzidine.
Statistical analyses
Values are expressed as the median and the 75th and 90th
percentiles of anti-p53 index levels. Statistical analyses were
performed using the SPSS Base SystemTm' and Advanced
StatisticsT'm programs (SPSS. USA). Except for the chi-square and
Fisher's exact probability tests, non-parametric methods were
used. The significance of differences between two independent
groups was determined by the Mann-Whitney U-test and the
significance of differences among more than two groups was
determined by Kruskal-Wallis one-way analysis. To estimate the
importance of factors associated with elevated serum anti-p53
index level, logistic regression analysis was performed in back-
ward step-wise fashion. Removal testing was based on the proba-
bility ofthe likelihood ratio statistic based on maximum likelihood
estimates. A receiver operating characteristics (ROC) curve was
constructedusing the CLABROC program (Metz. 1991). Values of
P less than 0.05 in two-tailed analyses were considered significant.
RESULTS
Serum anti-p53 index levels in lung cancer patients and
normal volunteers
The median levels of serum anti-p53 index were 6.6 for patients
with lung cancer and 1.7 for normal volunteers (Figure 1): there
was a statistically significant difference between these two groups
(P = 0.0000). although significant differences were also found
between the two groups not only in age (P =0.0000) but also in the
proportion ofindividuals with previous orconcomitant cancer(P=
0.0027) (Table 1). Among normal volunteers, there were no differ-
ences in anti-p53 index level by age (1.5. < 29 years ofage vs 2.0.
> 29: P = 0.6046). However. a significant difference in level was
found by gender (1.1. male vs 2.2. female: P = 0.0001). Among
lung cancer patients. there were no differences in anti-p53 index
level by gender (8.7. male vs 4.7. female: P = 0.1015). age (4.0.
< 68 years of age vs 8.2. > 68: P = 0.1152). smoking index (3.6.
smoking index < 600 vs 8.7. 2 600: P = 0.0903). presence of
previous or concomitant cancer (6.9. no vs 0.6. yes: P = 0.1074).
or disease stage (6.9. stage I vs 10.2. iLIAAiHB vs 5.7. IV: P =
0.1611). However, significant differences in index levels were
found by histology (4.3. adenocarcinoma vs 8.7. squamous cell
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Figure 1 Distribution of serum ant-ip53 antibody index levels for patients with lung cancer and normal volunteers. Values are presented as upper and lower
quartile and range (box), median value (horizontal line), and the middle 90% dstribution (whisker line). The dashed lines indicate the cut-off levels of the
anti-p53 antibody index (3.6 or 7.2, determined using the 95% specificity level for normal volunteers). Each sensitivity was determined using a cut-off level of
3.6 (t) or 7.2 (§). The correlation between the anti-p53 antibody index level and result of immunobloting analysis for 14 patients with lung cancer is also
demonstrated (0, antip53 antibody-positive by immunoblotting; a, antibody-negative). Adeno, adenocardnoma, large, large-cell carcinoma; normal, normal
volunteers; small, small-cell carcinoma; squamous, squamous cell carcinoma
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Figure 2 Detection of serum anti-p53 antibodies in patients with lung
cancer by immunoblotting analysis. Of 14 patients examined, results for
seven are demonstrated and arrarned from highest to lwest ant-p53
antiboody index levels (Lanes 1-7). M, molecular markers; MW, moeular
weight; N, negative control (phosphate-buffered saline containing 1% skim
milk); P, positive control (HEL 92.1.7 cells)
carcinoma vs 64.8. large-cell carcinoma vs 9.8. small-cell carci-
noma; P = 0.0109) (Figure 1). The highest anti-p53 index level
was found for large-cell carcinoma (P = 0.0330 compared with
adenocarcinoma. P = 0.0437 compared with squamous cell carci-
noma). In addition, small-cell carcinoma had a high index level
compared with adenocarcinoma (P = 0.0121).
Detection of serum ant-p53 by immunoblotting
analysis
Ofthe 14 serum samples obtained from lung cancer patients exam-
ined. anti-p53 antibodies were detected in three samples by our
immunoblotting assay. Figure 2 shows some ofthese results. These
positive samples had high anti-p53 index levels (%.5, 76.7. and
52.9 respectively). Antibodies were not detected in the samples
with low anti-p53 index levels below 50.0 (Figures 1 and 2).
Sensitivity ofanti-p53 index level in detection of lung
cancer
Except for 20 serum samples with a high anti-p53 index level
above the upper limit of measurement (n = 3) or low level below
the lower limit (n = 17). the anti-p53 index levels could be contin-
uously plotted in our series of lung cancer patients and normal
volunteers. although the presence of antibodies in serum was not
confinued for the samples with a low anti-p53 index level by our
immunoblotting assay. Therefore. the cut-off value for the serum
anti-p53 index was set at 3.6. in accordance with the 95% speci-
ficity approach recommended by Klapdor (1992). The sensitivities
of the anti-p53 index were 65.4% for all lung cancers. 52.0% for
adenocarcinoma. 66.7% for squamous cell carcinoma and 100%
for both large-cell carcinoma and small-cell carcinoma (Figure 1).
The sensitivity ofthe anti-p53 index for small-cell carcinoma was
significantly higher than that for adenocarcinoma (P = 0.0230). In
addition. when the cut-off value was set at 7.2. which corre-
sponded to twice the 95% specificity level for normal volunteers.
the sensitivities were 46.1% for all lung cancer. 28.0% for
adenocarcinoma. 55.6% for squamous cell carcinoma. 100% for
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Figure 3 Receiver operating characteristics curve for serum anti-p53
antibody index level for patents with lung cancer
large-cell carcinoma and 71.4% for small-cell carcinoma (Figure
1). With this cut-offvalue, the sensitivity ofthe anti-p53 index for
squamous cell carcinoma was significantly higher than that for
adenocarcinoma (P = 0.0359).
The ROC curve for the anti-p53 index for patients with lung
cancer is shown in Figure 3. This curve demonstrated that the
serum anti-p53 index had both high sensitivity and specificity for
the detection of lung cancer in this study. This index thus appears
to be useful as a marker oflung cancer at its initial presentation.
Multivariate analysis of factors associated with
elevated anti-p53 index level in sera of lung cancer
The factors associated with elevated anti-p53 index level (2 3.6.
determined using the 95% specificity level for normal volunteers
in this study) for lung cancer patients were further assessed using
logistic regression analysis. All the parameters listed in Table 1
were included and analysed in backward step-wise fashion. The
model finally selected [X2 (5) = 19.6. P = 0.0015] is shown in
Table 2. In this model, histology was a dominant factor associated
with elevated anti-p53 index level (P = 0.0255). Gender. age and
smoking index were selected as factors influencing index level.
but their probabilities did not reach significance (P = 0.0586. P =
0.0847. P = 0.0911 respectively). In addition, previous or
concomitant cancer was selected as a reverse factor. Disease stage
was not selected in this regression model. Furthermore. in the
model using the cut-off value of 7.2 [X2 (1) = 6.9. P = 0.0084].
histology was a dominant factor associated with elevated anti-p53
index level (P = 0.0184) (Table 2).
DISCUSSION
In our prospective study using a series of serum samples obtained
from patients newly diagnosed with lung cancer and normal
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Table 2 Multivariate analysis of factors associated with elevated serum anti-p53 antibody index level in lung cancer patients
Parameters s.e. Wald P-value
Cut-off level > 3.6
Histology (adeno vs squamous vs large vs small) 1.2717 0.5692 4.9919 0.0255
Gender (male vs female) 3.7045 1.9591 3.5756 0.0586
Presence of previous or concomitant cancer (no vs yes) -2.0188 1.1499 3.0822 0.0792
Age (< 68 years vs > 68) 1.3240 0.7681 2.9714 0.0847
Smoking index (< 600 vs > 600) 3.0217 1.7885 2.8544 0.0911
Cut-off level > 7.2
Histology (adeno vs squamous vs large vs small) 0.8013 0.3398 5.5594 0.0184
Elevated serum anti-p53 index level was defined as > 3.6 based on the 950o specificity level for normal volunteers. Analysis using the cut-off level of 7.2. which
corresponded to twice the 95%O specificty level, was also performed. The categorized variables for each parameter were encoded as 0. 1. 2 and 3 in the left
order in this logistic regression analysis. Abbreviations: adeno. adenocarcinoma: large. large-cell carcinoma; small. small-cell carcinoma: squarmous. squamous
cell carcinoma.
volunteers. serum anti-p53 level was found to be higher in lung
cancer patients than in normal volunteers. For lung cancer patients.
a significant difference in index levels was found by histolo ical
type of tumour: based on the cut-off value corresponding to twice
the 95%r specificity level for normal volunteers. elevated anti-p53
levels were found in 28.0c% of patients with adenocarcinoma.
55.6%7 ofthose with squamous cell carcinoma. 100%7c ofthose with
large-cell carcinoma and 71.4A/%c of those with small-cell carci-
noma. These incidences were higher than those noted in previous
studies including various types of cancer (Crawfort et al. 1982:
Caron de Fromentel et al. 1987: Davidoff et al. 1992: Schlichtholz
et al. 1992. 1994: Winter et al. 1992. 1993: Labrecque et al. 1993:
Lubin et al. 1993: Green et al. 1994: Mudenda et al. 1994: Muller
et al. 1994: Chana et al. 1995). In a lunc cancer series.
Schlichtholz et al (1994) reported that anti-p53 antibodies were
found in sera in 20.0% of patients with adenocarcinoma. 11.1%' of
those with squamous cell carcinoma. 40.0%7 of those with large-
cell carcinoma and 44.4%/ ofthose with small-cell carcinoma. This
difference in incidences from those in our study is clearly due to
differences in the criteria used in the two studies. Schlichtholz et al
(1994) defined a 'positive' finding of anti-p53 in serum as
absorbance at least equal to that of anti-p53-positive control
serum. which was demonstrated to have anti-p53 by both irimuno-
precipitation and immunoblotting assays. However. in our studv.
elevated' anti-p53 level was defined in accordance with the 95%/
specificity approach for normal volunteers. The criteria used b-
Schlichtholz et al (1994) are valid. In fact. presence of anti-p53
was confirmed only for sera with a high anti-p53 index level in our
immunoblotting, assay. However. the frequency of false-negative
findings for anti-p53 might be increased with the use of these
criteria. as. in general. immunoblottin2 and immunoprecipitation
assays have lower sensitivity for detection oftarget molecules than
Joes ELISA. In addition. according to two independent studies
[Schlichtholz et al. 1994: Trivers et al. 1996) as well as our own.
anti-p53 levels determined by ELISA are continuously plotted for
:ancer patients and appear to be higher than those in normal
control subjects. We therefore believe that the 95%k specificity
approach may be clinically useful for the detection ofanti-p53.
Concerning the relationship between elevated anti-p53 levels
and clinical features of lung cancer patients. histological type of
umour was found to be a dominant factor affecting elevation of
mti-p53 level in our logistic regression model. Large-cell
carcinoma and small-cell carcinoma both demonstrated elevated
inti-p53 levels. This finding is similar to that reported by%
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Schlichtholz et al (1994). and is supported by the findino of hiah
p53 gene mutation frequencies in lung cancer tumours. e.g. 55%e for
non-small-cell lung cancer tumours and 78%7 for small-cell lung
cancertumours (Johnson. 1995). These findings indicate that serum
anti-p53 index level is a marker for both large-cell carcinoma and
small-cell carcinoma. and. that is to say, its elevation minht be
correlated with tumour histology showing rapid grow-th. However.
no relationship was found between elevated serum anti-p53 index
level and disease stage. We therefore speculate that anti-p53 index
level might be independent of tumour burden and disease stage in
cancerpatients. based on the following findings: (1 ) that emergence
of serum anti-p53 was demonstrated before clinical detection of
cancers in a subset of a non-cancer cohort (Lubin et al. 1995:
Triyers et al. 1995. 1996): (2) that serum levels of anti-p53
remained constant in cancer patients ifcurative treatment could not
be performed (Schlichtholz et al. 1994). Notably. the anti-p53
serum index has the potential for use in early diagnosis of cancers.
The presence of p53 gene mutation has been demonstrated in
premalignant bronchial lesions such as mild and severe epithelial
dvsplasias (Sundaresan et al. 1992). Therefore. heavy smokin2.
which leads to bronchial epithelial dysplasia. might elevate serum
anti-p53 index level. In addition. in our study. no correlation was
found between elevated serum anti-p53 level and the presence of
previous orconcomitant cancer. although Mudenda et al ( 1994) did
find a positive correlation between these two. A large cohort study
will be needed to determine the true nature ofthis correlation.
In conclusion. in our studv using a series ofserum samples from
patients newly diagnosed with lung cancer. serum anti-p53 index
level appeared possibly to be independent of tumour burden and
the presence of previous or concomitant cancer. but was stronalv
correlated with tumour histological type.
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